Linking pharmacoeconomic analyses to results of systematic review and meta-analysis

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 3, Issue 4, 2003, Pages 441-448

  Jordan, Harmon S ^a   Lau, Joseph ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

Meta analysis; Pharmacoeconomic analysis; Summarizing data; Systematic review

Indexed keywords

ALPHA2B INTERFERON; AMOXICILLIN; ANTIBIOTIC AGENT; CLARITHROMYCIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOLIC ACID ANTAGONIST; IMIDAZOLE DERIVATIVE; OMEPRAZOLE;

CLINICAL RESEARCH; CLINICAL TRIAL; CONFIDENCE INTERVAL; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; ECONOMIC ASPECT; EXPERIMENTAL DESIGN; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HEPATITIS C; HUMAN; MEDICAL DECISION MAKING; META ANALYSIS; METHODOLOGY; OUTCOMES RESEARCH; QUANTITATIVE ANALYSIS; RELIABILITY; RESOURCE ALLOCATION; REVIEW; SENSITIVITY AND SPECIFICITY; SINUSITIS;

EID: 0042562095     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.3.4.441     Document Type: Review

References (44)

1. Bootman JL, Townsend RJ, McGhan WF. Principles of Pharmacoeconomics. W Harvey Whitney Books Company, Cincinnati, OH, USA (1991).
2. Drummond M. Guidelines for pharmacoeconomics studies. The way forward. PharmacoEconomics 6, 493-497 (1994).
3. Mauskopf H. Why study Pharmacoeconomics? Expert Rev. Pharmacoeconomics Outcomes Res. 1(1), 1-3 (2001).
4. Lafata JE, Koch GG, Ward RE. Synthesizing evidence from multiple studies. Med. Care (Suppl) 34(12), DS136-DS145 (1996).
5. Balk EM, Zucker DR, Engels EA, Wong JB, Williams JW, Lau J. Strategies for diagnosing and treating acute bacterial sinusitis: a cost-effectiveness analysis. J. Gen. Intern. Med. 16, 701-711 (2001).
6. Hill S, Mitchell A, Henry D. Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA 283(16), 2116-2121 (2000).
7. Moriguchi H, Uemura T, Kobayashi M, Chung RT, Sato C. Management strategies using pharmacogenomics in patients with severe HCV-1b infection: a decision analysis. Hepatology 36(1), 177-185 (2003).
8. Smith ML, Glass GV. Meta-analysis of psychotherapy outcome studies. American Psychologist 32, 752-760 (1977). In: Practical Meta-analysis. Sage Publications. Lipsey MW, Wilson DB (Eds). Thousand Oaks, CA, USA (2001).
9. Petitti DB. Meta-analysis, Decision Analysis and Cost-Effectiveness Analysis. Methods for quantitative Synthesis in Medicine. Oxford University Press, NY, USA (2000).
10. Sanchez L. Applied pharmacoeconomics. Am. J. Health System Pharmacy 56 (12), 1630-1638 (1999).
11. Lau J, Ioannidis JPA, Schmid CH. Quantitative synthesis in systematic reviews. Ann. Intern. Med. 127, 820-826 (1997).
12. Clarke MJ, Stewart LA. Principles of and procedures for systematic reviews. In: Systematic Reviews in Healthcare: Meta-analysis in Context. Egger M, Smith G, Altman D (Eds). BMJ Publishing Group, London, UK, 23-41 (2001).
13. Counsell C. Formulating questions and locating primary studies for inclusion in systematic reviews. Ann. Intern. Med. 127, 380-387 (1997).
14. Vickers A, Goyal N, Harland R, Rees R. Do certain countries produce only positive results? A systematic review of controlled trials. Controlled Clin. Trials 19, 159-166 (1998).
15. Lau J, Ioannidis JPA, Schmid CH. Summing up evidence: one answer is not always enough. Lancet 351, 123-127 (1998).
16. Ioannidis JPA, Haidich AB, Pappa M et al. Comparisons between randomized and nonrandomized evidence. JAMA 286, 821-830 (2001).
17. Moher D, Jadad AR, Nichol G et al. Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists. Controlled Clin. Trials 16, 62-73 (1995).
18. Meade MO, Richardson WS. Selecting and appraising studies for a systematic review. Ann. Intern. Med. 127, 531-537 (1997).
19. Juni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 282, 1054-1060 (1999).
20. Schulz K, Chalmers I, Hayes R, Altman D. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273(5), 408-412 (1995).
21. Balk EM, Bonis PO, Moscowitz HSCH, Ioannidis JP, Wang C, Lau J. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. JAMA 287(22), 2973-2982 (2002).
22. Laird NM, Mosteller F. Some statistical methods for combining experimental results. Int. J. Tech. Assess. Health. Care 6, 5-30 (1990).
23. Lau J, Ioannidis JPA, Schmid CH. Quantitative synthesis in systematic reviews. Ann. Intern. Med. 127, 820-826 (1997).
24. Normand ST. Meta-analysis: formulating, evaluating, combining and reporting. Stat. Med. 18, 321-359 (1999).
25. Engels EA, Schmid CH, Terrin N, Olkin I, Lau J. Heterogeneity and statistical significant in meta-analysis: an empirical study of 125 meta-analyses. Stat. Med. 19, 1707-1728 (2000).
26. Dersimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin. Trials 7, 177-188 (1986).
27. Schmid CH. Using Bayesian inference to perform meta-analysis. Evaluation Health Professions 24, 165-189 (2001).
28. Schmid CH, Whiting G, Cory D, Ross S, Chalmers TC. Omeprazole plus antibiotics in the eradication of Helicobacter pylori infection: a meta-regression analysis of randomized, controlled trials. Am. J. Therapeutics 6, 25-36 (1999).
29. Furukawa TA, Streiner DL, Hori S. Discrepancies among megatrials. J. Clin. Epidemiol 53, 1193-1199 (2000).
30. Schmid CH. Exploring heterogeneity in randomized trials via meta-analysis. Drug Information J. 33, 211-224 (1999).
31. Berkey CS, Hoaglin DC, Mosteller F, Colditz GA. A random-effects regression model for meta-analysis. Stat. Med 14, 395-411 (1995).
32. Van Houwelingen HC, Arends LR, Stipnen T. Advanced methods in meta-analysis, multivariate approach and meta-regression. Stat. Med. 21, 589-624 (2002).
33. Clarke MJ, Stewart LA. Obtaining individual patient data from randomized controlled studies. In: Systematic Reviews in Healthcare: Meta-analysis in Context. Egger M, Smith G, Altman D (Eds). BMJ Publishing Group, London, UK 109-121 (2001).
34. Anderson S, Auquier A, Hauck WW, Oakes D, Vandaele W, Weisberg H. Statistical Methods for Comparative Studies. John Wiley and Sons, NY, USA 125 (1980).
35. Ioannidis JP. Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. JAMA 279(4), 281-286 (1998).
36. Thornton A, Lee P. Publication bias in meta-analysis: its causes and consequences. J. Clin. Epidemiol. 53, 207-216 (2000).
37. Tang JL, Liu JL. Misleading funnel plot for detection of bias in meta-analysis. J. Clin. Epidemiol. 53(5), 477-484 (2000).
38. Ioannidis JPA, Lau J. Reporting of the safety of medications in randomized trials is neglected: an evaluation of 7 medical areas. JAMA 285, 437-443 (2001).
39. de Ferranti SD, Ioannidis JPA, Lau J, Anninger WV, Barza M. Are amoxicillin and filate inhibitors as effective as other antibiotics for acute sinusitis? A meta-analysis. Brit. Med. J. 317, 632-637 (1998).
40. Engels E, Barza M, Terrin N, Lau J. Meta-analysis of diagnostic tests for acute sinusitis. J. Clin. Epidemiol. 53, 852-862 (2000).
41. 2b in patients with histologically mild chronic hepatitis B. Ann. Inter. Med. 127(10), 855-865 (1997).
42. Drummond R, Luft H. Pharmacoeconomic analyses: making them transparent, making them credible. JAMA 283(18), 2158-2160 (2000).
43. Kassirer JP, Angell M. The Journal's policy on cost-effectiveness analysis. New Engl. J. Med. 331, 669-670 (1994).
44. Mulrow CD. The medical review article. Ann. Intern. Med. 106, 485-488 (1987).